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Background: Acute illness is the most common presentation of children to ambulatory care. In contrast, serious
infections are rare and often present at an early stage. To avoid complications or death, early recognition and
adequate referral are essential. In a recent large study children were included prospectively to construct a
symptom-based decision tree with a sensitivity and negative predictive value of nearly 100%. To reduce the number
of false positives, point-of-care tests might be useful, providing an immediate result at bedside. The most probable
candidate is C-reactive protein, as well as a pulse oximetry.
Methods: This is a diagnostic accuracy study of signs, symptoms and point-of-care tests for serious infections.
Acutely ill children presenting to a family physician or paediatrician will be included consecutively in Flanders,
Belgium. Children testing positive on the decision tree will get a point-of-care C-reactive protein test. Children testing
negative will randomly either receive a point-of-care C-reactive protein test or usual care. The outcome of interest is
hospital admission more than 24 hours with a serious infection within 10 days. Aiming to include over 6500 children,
we will report the diagnostic accuracy of the decision tree (+/− the point-of-care C-reactive protein test or pulse
oximetry) in sensitivity, specificity, positive and negative likelihood ratios, and positive and negative predictive values.
New diagnostic algorithms will be constructed through classification and regression tree and multiple logistic
regression analysis.
Discussion: We aim to improve detection of serious infections, and present a practical tool for diagnostic triage of
acutely ill children in primary care. We also aim to reduce the number of investigations and admissions in children
with non-serious infections.
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Acute illness is the most common reason for encounter
of children attending ambulatory care.
In a primary care setting, less than 1% of children
assessed will have a serious illness [1]. The incidence
of serious infections in children is assumed to be 5
to 10 times higher at the paediatric emergency de-
partment [2]. Febrile illness accounts for 20% of all
paediatric ED visits [3].
Serious infections are rare in children in developed
countries, but associated with considerable morbidity
and mortality [4]. In Flanders, infectious diseases are re-
sponsible for 8.0% of all deaths in children under the age
of one year, and for 13.6% of deaths in children aged 1
to 14 years [1,5]. These numbers are comparable to
death rates previously reported in the UK [6]. Serious
infections in children are usually defined as sepsis, men-
ingitis, pneumonia, pyelonephritis, gastroenteritis with
dehydration, osteomyelitis, complicated abscess, viral re-
spiratory infection with hypoxia, and cellulitis [7]. The
mortality of meningococcal disease can be as high as
25% [8]. Besides this, approximately 7% of children who
survive bacterial meningitis suffer from hearing loss [9].
Serious infections need to be distinguished from the
vast majority of self-limiting viral conditions in children.
Those few children with a serious infection can present
at an early stage when the severity of the infection is not
yet apparent [4]. At that point, their symptoms tend to
mimic those of children with a non-serious illness. The
rapid deterioration could cause a diagnosis to be missed
at first contact, sometimes with severe consequences.
Early recognition and adequate referral of serious infec-
tions are of vital importance to avoid complications. A
faster and more accurate recognition of serious diseases
could prevent unnecessary investigations, referrals, treat-
ments and hospitalisations in children without serious
illness, avoiding traumatic experiences for the child, par-
ental concerns and health care expenditures.
Assessment of serious infections
Clinicians use signs and symptoms to assess the prob-
ability of a serious infection and to decide on further
management. To investigate the predictive value of these
signs and symptoms, Van den Bruel et al. conducted a
trial, which prospectively included almost 4000 children,
resulting in a decision tree based on signs and symptoms
[10]. This tree had a sensitivity and negative predictive
value of nearly 100%. The risk of having a serious infection
in children testing positive and thus indicating referral for
further testing, however, was approximately 10%. If applied
in clinical practice without caution, this decision tree could
cause far too many children to be referred to hospital.
Vital signs are uncommonly measured in children in
general practice [11]. If measurement of vital signs wouldbecome part of routine care, they could be useful in de-
tecting serious infections in acutely ill children [12,13].
A pulse oximetry, alongside other vital signs measure-
ments has shown to differentiate children with serious
infections from those with self-limiting infections in
paediatric emergency care [13]. Validation of these re-
sults in low prevalence settings might aid clinicians to
measure vital signs objectively.
A systematic review of the literature in all relevant da-
tabases identified the laboratory tests used to detect ser-
ious infections in febrile children in ambulatory settings
[14,15]. The most probable candidates for this purpose
are CRP and procalcitonin (PCT). CRP can predict bac-
terial aetiology of community-acquired pneumonia [16].
PCT correlates with severity of urinary tract infections
and sepsis and of community-acquired pneumonia in
children [17,18]. Despite these promising results, evi-
dence is not yet conclusive and other tests may be valu-
able as well, urging for a large-scale trial.
POC tests are defined as laboratory and other services
provided to patients at bedside. The physician has an im-
mediate result and management can be adjusted accord-
ingly. This makes them especially attractive in situations
where a fast decision is warranted, such as urgent-access
ambulatory care. They are minimally invasive, and thus
relevant in paediatric care.
In diagnostic tests and clinical prediction rules a sensi-
tivity of 100% is hard to achieve, because patients
present at different stages in the evolution of their ill-
ness. At an early stage classic “red flag” features of ser-
ious illnesses tend to be absent. Safety netting is an
integral part of the diagnostic process to deal with this
situation. Neighbour and Almond et al. defined safety
netting and sought clinical consensus about what safety
netting should include: (I) the existence of uncertainty
and how to communicate this to the patient or parent,
(II) what exactly to look out for, (III) guidance on how
exactly to seek further help and (IV) what to expect
about time course [19-21]. Safety netting strategies and
subsequent action should be evaluated on their effect on
patient outcome, referral rate, antibiotic prescribing, and
parental anxiety. In the ERNIE 2 trial, we will provide
formal safety netting to a random sample of all children
with a negative result on the decision tree, as described
by Lemiengre et al. [22]. This includes a parent leaflet
with instructions on how to detect and treat certain
symptoms (e.g. fever), or a deterioration of the child’s
condition, as well as when and how to re-consult the
physician.
In this study, we aim to validate this decision tree in a
new population and explore the added value of techno-
logical tests, such as Point-of-Care (POC) tests in diagnos-
ing serious infection in acutely ill children in ambulatory
care.
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comprehends a cluster randomised controlled trial to
evaluate the effect of a POC CRP test and a brief
intervention combined with a written safety net advice
on additional testing, re-consultation and the antibiotic
prescribing rate in acutely ill children not suspected
of serious disease in primary care, as described by
Lemiengre et al. [22].
Methods
Design
This is a prospective diagnostic accuracy study in ambu-
latory care (defined as general practice, paediatric out-
patient clinics or emergency departments) identifying
the diagnostic value of signs, symptoms and techno-
logical tests in diagnosing serious infections using hospital
admission more than 24 hours for a serious infection as
the main outcome measure (Figure 1).
Participants
Children aged 1 month to 16 years, presenting to a fam-
ily physician or paediatrician in Flanders, Belgium, with
a new acute illness episode of maximum 5 days will be
included consecutively. Children will be excluded if the
acute illness is caused by merely traumatic or neuro-
logical conditions, intoxication, psychiatric or behav-
ioural problem, or an exacerbation of a known chronic
condition. If a physician includes the same child twice
within 5 days, we will consider the second registration
as a repeated measure and discard it subsequently from
the analysis. Physicians will be instructed to recruit chil-
dren consecutively during the inclusion period. If a
physician includes less than five children over the studyFigure 1 Study design. POC CRP, point-of-care C-reactive protein; m, monperiod, the assumption of consecutive inclusion is prob-
ably violated, and his or her results will subsequently be
excluded from the analysis.
Index tests
5-stage decision tree
As part of a thorough history taking and physical exam-
ination, we will ask physicians to score the 5-stage deci-
sion tree, as developed by Van den Bruel et al. [10].
Children testing positive on this tree will always get a
POC CRP test.
Children testing negative on this tree presenting to
primary care will either get a POC CRP test, or usual
care, depending on their per practice cluster randomisa-
tion, as described by Lemiengre et al. [22].
POC CRP test (finger stick)
We searched the literature in multiple databases and
performed a survey of manufacturers, completed with
personal contacts in order to identify tests that would be
marketed shortly for acute infections in children in pri-
mary care. For use in children, important criteria of a
feasible test are the sample volume (<5 μl) and the
test duration (<5 minutes). Two point-of-care CRP
tests (Afinion CRP test on the Afinion AS100 Analyzer,
Alere, USA and CRP test on the LifeAssays™ Reader by
LifeAssays, Sweden) met our criteria.
A pilot study was performed to determine the user-
friendliness of these POC CRP devices. Only the Afinion
CRP test on the Afinion AS100 Analyzer met our stan-
dards for user-friendliness. It is a user-friendly device,
especially because a small drop of blood is enough to
perform the test, what makes it perfect for use inth; y, year.
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get the result (aspirating blood in the capillary, putting
the cassette in the machine). In this pilot study, the ana-
lytical accuracy of the selected POC CRP device was also
examined, demonstrating an agreement between the
CRP test results on the Afinion AS100 Analyzer and the
Cobas c702 (Roche Diagnostics, Switzerland) with a
mean difference of 0.1% (95% CI: −17.6% to 17.4%) and
perfect correlation (y = 1.01×-0.04) even at high CRP
concentrations [23].
The Afinion™ CRP Test Cartridge consist of a 1.5 μL
glass capillary to be filled with blood from a finger stick
and a reagent container. First, the sample is automatic-
ally diluted with a liquid that also lyses the blood cells.
Then, the sample mixture is aspirated through the mem-
brane coated with anti-CRP antibodies, and all CRP in
the sample is concentrated on this membrane. The con-
jugate solution containing anti-CRP antibodies labelled
with ultra-small gold particles is then sucked through
the membrane. The gold-antibody conjugate binds to
the immobilized CRP on the membrane, which will turn
red-brown. Excess gold-antibody conjugate is removed
by a washing solution. The analyser measures the colour
intensity of the membrane, which is proportional to the
amount of CRP in the sample. The result is available
within 4 minutes. The CRP measuring range is 5–
150 mg/L.
We will instruct all physicians to properly perform
the POC CRP test. For internal quality control, a low
and a high control positive will be measured at regu-
lar intervals to confirm the efficacy and correct per-
formance of the test according to the manufacturer’s
instructions. The device distributor will provide tech-
nical assistance.
Pulse oximetry
All physicians will be asked to measure pulse oximetry by
means of a paediatric finger pulse oximeter (CMS50QA,
Contec™ Medical Systems, China), provided for this trial,
measuring oxygen saturation and pulse rate. A small-scale
pilot study was performed to determine the appropriate
age requirements for the device (above 3 years of age) and
agreement with a large-size pulse oximeter.
Outcome measures
Primary outcome measure
1. Serious infections, defined as a hospital admission for
more than 24 hours for any of these diagnoses:
– Sepsis (including bacteraemia) with a pathogenic
bacteria isolated from a haemoculture as the
reference standard
– Meningitis (viral or bacterial) with a positive lumbar
puncture (pleocytosis in cerebrospinal fluid andidentification of a bacteria or a virus) as the
reference standard
– Abscess with a positive culture as the reference standard
– Pneumonia (viral or bacterial) with an infiltrate seen
on chest x-ray as the reference standard
– Osteomyelitis (pathogens from bone aspirate as the
reference standard, or if unavailable with a MRI or
bone scan suggestive for osteomyelitis)
– Cellulitis (acute suppurative inflammation of the
subcutaneous tissues)
– Gastro-enteritis with dehydration
– Complicated urinary tract infection (positive urine
culture (>105/ml pathogens of a single species) and
systemic effects such as fever)
– Viral respiratory tract infections complicated by
hypoxia (e.g. bronchiolitis)
If a serious infection occurs within 10 days after inclu-
sion, it will be considered a consequence of the same
illness episode. To ensure a firm definition of the out-
come (a serious infection), the outcome will be measured
through three strategies: (I) a thorough search of each
child’s electronic medical record at the hospitals within
the referral region of the participating FP or paediatri-
cian, (II) the results from interviewing the physician who
included the child in the study, and finally (III) the results
from the diary filled out by parents after consulting the
FP, mentioning the date the child is no longer ill.
Secondary outcome measure
1. Use of other diagnostic tests and medical services
(including re-consultation).
Sample size
Based on the binomial distribution, at an expected sensi-
tivity of 97% with a minimal acceptable lower confidence
limit of 85%, the minimal number of cases is 59, not tak-
ing into account the non-monotonic nature of power as
a function of sample size due to discreteness of the bino-
mial distribution [24]. The number of controls, derived
through the formula Ncontrols = Ncases [(1-Prevalence)/
Prevalence], [25] is 7316 at a prevalence of 0.8% and
6497 at a prevalence of 0.9%.
Considering the sample size calculation, we aimed to
include 6500 children (in 88 general practices and 12
paediatric units), across Flanders, in urban and rural
areas over a period of 12 months.
Implementation
Recruitment of physicians
We will compose a letter with a short description of the
research and the (dis)advantages of participating, with
the option to request further information. This letter will
be distributed by email to all FPs known to the research
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terested family physicians (FPs) will be contacted and
visited by the researchers to inform them more exten-
sively about the trial. Participating FPs will complete
a short questionnaire about practice characteristics.
For more details about this questionnaire, we refer to
Lemiengre et al. [22]. After agreement to participate, all
physicians will be visited and instructed on the inclusion
process. At this point in time, we will inform the FPs
about their allocation by the investigator. The step-by-
step plan will be explained in detail. All FPs will get a
demonstration to properly perform the POC CRP test.
We will ask the paediatricians involved in the project
steering committee and their colleagues affiliated with a
university hospital to participate in the study and include
eligible children at the outpatient clinic, as well as the
emergency department. We’ll ask them to contact other
interested colleagues affiliated with hospitals across
Flanders, with a workload of acutely ill children similar
or higher compared to the university hospitals. After
agreement to participate, a meeting with all participat-
ing paediatricians will be organised to explain the trial
in detail. All paediatricians will get a demonstration to
perform the POC CRP test.
Parents will be informed through posters in the wait-
ing room, as well as flyers, with a short comprehensible
description of the background, aims and requirements
to participate. Physicians will inform every eligible child
and their parent(s), delivering an information leaflet and
asking formally to participate. Parents and children from
the age of 12 will sign a written informed consent form,
with a permission to access the hospital medical record
in case of a possible admission. We will provide adjusted
information leaflets and consent forms for minors below
and above 12 years of age.
We will ask physicians to perform a thorough history
taking and physical examination of every child, register-
ing items based on experience from previous research
and clinical consensus of an international team of clini-
cians and researchers, [26] such as measurement of the
NICE traffic light system, the Yale Observation Scale,
the 5-stage decision tree, and vital signs, such as a pulse
oximetry [27-29].
The clinician will record the gathered data, prelimin-
ary diagnosis and planned actions (e.g. investigations,
treatment or referral) on a case report form. Only par-
ents of children attending a FP’s office will complete a
booklet, containing 4 surveys and a follow up diary. For
more details about this booklet and the related proce-
dures, we refer to Lemiengre et al. [22].
We will ask parents to send a text message to the in-
vestigators on the day the child is no longer sick. These
children will automatically enter a prize draw and prices
will be awarded monthly amongst these children.Follow-up
We intend to contact physicians at least on a monthly
basis, via email, telephone or regular mail, as well as use
occasional motivational gifts to remind them of this trial
and encourage consecutive inclusions. A gift-savings sys-
tem for physicians will be introduced with children toys
for the doctor’s waiting room.
If a physician is clearly not including children or vio-
lating the in- or exclusion criteria of this study, the trial
will be discontinued in this practice and replaced by a
new motivated practice willing to participate, with simi-
lar practice type and region.
Collaborating organizations
The research partners are:
– The Department of General Practice, Faculty of
Medicine, KU Leuven, in collaboration with the
Clinical Department of Paediatrics, UZ Leuven
– The Department of Family Practice and Primary
Health Care, Faculty of Medicine and Health
Sciences, Ghent University, in collaboration with the
Department of Paediatrics, UZ Gent.
Ethics
The protocol of this study was approved by the Ethical
Review Board of the University Hospitals/KU Leuven,
under reference ML8601. All children’s parents are re-
quested to provide written informed consent. As soon as
all hospitals within the referral region of all participating
FPs are known, these centres will be submitted for for-
mal approval by the coordinating and the local ethical
review boards.
Statistical analysis
The data will be stored and analysed at two locations,
KU Leuven and Ghent University, using Excel (Microsoft
Corporation, Redmond, USA), Stata software (version
11.2; Stata Corp., College Station, TX, USA), SPSS
(version 20; SPPS Inc., Chicago, Illinois, USA) and
QSR NVivo version 10 (QSR International Pty Ltd,
Melbourne, Australia).
The diagnostic accuracy of the 5-stage decision tree
will be tested and reported in sensitivity, specificity,
positive and negative likelihood ratios, and positive and
negative predictive values with their 95% confidence
intervals (CI). Whenever possible, Receiver Operating
Characteristic (ROC) curves will be plotted in order to
identify the optimal cut-off value, as well as forest and
dumbbell plots of positive and negative predictive value
for presentational purposes [4]. The value of the POC
CRP test and the pulse oximetry will each be added to
the 5-stage decision tree and compared to the results of
the 5-stage decision tree alone, to determine the added
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rithms will be constructed through Classification and
Regression Tree and multiple logistic regression analysis,
while accounting for all clinically plausible interactions,
resulting in a new multivariable model. Goodness-of-fit
and discrimination testing will be performed, as well as
regression diagnostics to look for individuals with exces-
sive influence on the model.
We will compare the use of additional diagnostic tests,
medical services and re-consultation between children
who always get a POC CRP test, and children who only
get a POC CRP test after a positive result on the deci-
sion tree. We will balance the costs and benefits of this
intervention.
Discussion
Feverish illness is the most common reason for encoun-
ter of children attending ambulatory care. In contrast,
serious infections are rare in children in developed
countries, but associated with considerable morbidity
and mortality.
Those few children with a SI can present at an early
stage when the severity of the infection is not yet appar-
ent. A faster and more accurate recognition of serious
diseases could prevent unnecessary investigations, refer-
rals, treatments and hospitalisations in children without
serious illness. On the other hand, children with appar-
ent signs of a life-threatening serious infection should
immediately be referred to or seen at the ED or an
urgent-access paediatric clinic. Unnecessary delay of ad-
equate treatment and management decisions should be
avoided in these children.
Signs and symptoms are the first information to sup-
port clinical decision making in primary care [30]. Par-
ental concern is an important predictor of SI, as well as
the clinician’s feeling that “something is wrong” (gut
feeling) [10]. Other red flags, such as cyanosis, rapid
breathing, poor peripheral circulation, meningeal irrita-
tion and petechial rash have been shown to increase the
likelihood of a serious infection in ill children [4].
Blood tests are only rarely performed in acutely ill
children in primary care, due to the need to make
management decisions prior to the availability of test
results. Very little research has been performed in am-
bulatory care and none of it in primary care specifically.
However, a role has been put out for CRP and procalci-
tonin to rule out serious infections [15].
POC tests enable physicians to adjust their manage-
ment according to the immediate test results. They are
minimally invasive, and thus relevant in paediatric care.
Research is needed to further inform clinicians and
parents. Triage, face-to-face assessment in primary care,
as well as evaluating clinical features, laboratory tests
and safety netting, needs to be further examined [30].To our knowledge, this is the first large-scale trial,
investigating the (added) value of POC CRP in addition
to clinical features in identifying serious infections in
acutely ill children in ambulatory care, including general
practice, paediatric outpatient clinics and hospital emer-
gency departments.
Currently, no reliable cut-offs for CRP are known to
differentiate between viral and bacterial causes of acute
infection in children, nor for referral or discriminating
between serious infections and self-limiting disorders.
Therefore, physicians did not receive any guidance on
the interpretation of the CRP results. Furthermore, we
did not impose any restriction on the physicians’ care
concerning treatment, additional testing, referral or hos-
pital admission.
The main challenges of this project will be recruitment
of study participants, avoidance of non-consecutive inclu-
sions, and verification of the outcome measures. To ensure
sufficient recruitment, several reminders through various
ways and small presents for all participating physicians will
be provided, endorsed by a personal approach. We also
made sure to use very small finger-stick devices which
cause only very limited pain or discomfort to the children,
which were subsequently rewarded with a small present
(finger-puppet). If a physician includes less than five chil-
dren over the study period, the assumption of consecutive
inclusion is probably violated, and his or her results will be
excluded from the analysis.
To ensure a firm definition of the serious infections,
the outcome was measured through three different strat-
egies, which is the clinically sensible thing to do.
In diagnostic accuracy studies with low prevalence of
the target condition, it is often difficult to calculate the
required sample size with sufficient power. A recent de-
veloped nomogram to calculate sample size in diagnostic
studies was not useful, because prevalences below 1%
were not computed in the nomogram [31].
We aim to improve detection of SI, and present a
practical tool for diagnostic triage of these children in
primary care. We also aim to reduce the number of in-
vestigations and admissions in children with non-serious
infections.
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